je.st
news
Teva Announces FDA Approval Of ProAir RespiClick
2015-04-22 08:17:13| dairynetwork News Articles
Teva Pharmaceutical Industries Ltd., recently announced that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol sulfate) inhalation powder, a breath-actuated, multi-dose, dry-powder, short-acting beta-agonist (SABA) inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm (EIB) in patients 12 years of age and older
Tags: approval
announces
fda
teva
Category:Agriculture and Forestry